



PATENT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-618)

In the Application of:

Cartier, et al.

Serial No.: 09/856,349

Filing Date: May 18, 2001

For: Multivalent T.D. Polio Vaccine Against  
At Least Diphtheria, Poliomyelitis and  
Tetanus

Examiner: Not Yet Assigned

Group Art Unit: Not yet Assigned

TRANSMITTAL LETTER

Commissioner for Patents  
Washington, D.C. 20231


Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
  - a) Information Disclosure Statement;
  - b) PTO Form 1449 and ten (10) references cited therein; and
  - c) return receipt postcard.
2. With respect to fees:
  - a) A fee is not required at this time.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on October 4, 2001.

Date: October 4, 2001

Respectfully submitted,

  
Michael S. Greenfield  
Registration No. 37,142



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-618)

In the Application of:

Cartier, et al.

Serial No.: 09/856,349

Filing Date: May 18, 2001

For: Multivalent T.D. Polio Vaccine Against  
At Least Diphtheria, Poliomyelitis and  
Tetanus

Examiner: Not Yet Assigned

Group Art Unit: Not yet Assigned

**INFORMATION DISCLOSURE STATEMENT**

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO Form 1449.


In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

**CERTIFICATE OF MAILING (37 C.F.R. 1.8a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington D.C. 20231, on October 4, 2001.

Date: October 4, 2001

  
Michael S. Greenfield

## **FOREIGN PATENT DOCUMENTS**

1. International Patent Application No. WO 93/24148, published December 9, 1993.
2. International Patent Application No. WO 98/00167, published January 8, 1998.
3. International Patent Application No. WO 98/19702, published May 14, 1998.
4. International Patent Application No. WO 99/48525, published September 30, 1999.
5. International Patent Application No. WO 99/13906, published March 25, 1999.


## **OTHER DOCUMENTS**

6. Scheifele D. W., et al. "Can Reductions in Diphtheria Toxoid Or Aluminum Content Reduce the Reactogenicity of Booster Doses of DPT Vaccine?" *Immunology & Infectious Diseases*. Vol. 5, 1995, pp. 73-77.
7. Gupta and Siber, et al. "Adjuvants for human vaccines—current status, problems and future prospects." *Vaccine*. Vol. 13, No. 14, October 1, 1995, pp. 1263-76.
8. Galazka et al. "Immunization Against Diphtheria with Special Emphasis on Immunization of Adults." *Vaccine*. Vol. 14, No. 9, June 1, 1996, pp. 845-57.
9. Murdin et al. "Inactivated Poliovirus Vaccine: Past and Present Experience." *Vaccine*. Vol. 14, No. 8, June 1, 1996, pp. 735-46.
10. Laroche et al. "The Immunogenicity and Safety of a New Combined Diphtheria, Tetanus and Poliomyelitis Booster Vaccine (Td-eIPV)." *Infection*. Vol. 27, No. 1, January 1999, pp. 49-56.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff**

Date: October 4, 2001

By:

  
Michael S. Greenfield  
Reg. No. 37,142


FORM PTO-1449  
(Rev. 2-32)U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

01-618

Serial No.

09/856,349


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use several sheets if necessary)
Applicant:  
Cartier, et al.Filing Date:  
May 18, 2001Group:  
Not yet assigned**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclasses	Filing Date if Appropriate

**FOREIGN PATENT DOCUMENTS**

		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No
W	O	9	3	2	4	1	4	8	December 9, 1993	PCT				
W	O	9	8	0	0	1	6	7	January 8, 1998	PCT				
W	O	9	8	1	9	7	0	2	May 14, 1998	PCT				
W	O	9	9	4	8	5	2	5	September 30, 1999	PCT				
W	O	9	9	1	3	9	0	6	March 25, 1999	PCT				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

			Scheifele D. W., et al. "Can Reductions in Diphtheria Toxoid Or Aluminum Content Reduce the Reactogenicity of Booster Doses of DPT Vaccine?" <i>Immunology &amp; Infectious Diseases</i> . Vol. 5, 1995, pp. 73-77.
			Gupta and Siber, et al. "Adjuvants for human vaccines—current status, problems and future prospects." <i>Vaccine</i> . Vol. 13, No. 14, October 1, 1995, pp. 1263-76.
			Galazka et al. "Immunization Against Diphtheria with Special Emphasis on Immunization of Adults." <i>Vaccine</i> . Vol. 14, No. 9, June 1, 1996, pp. 845-57.
			Murdin et al. "Inactivated Poliovirus Vaccine: Past and Present Experience." <i>Vaccine</i> . Vol. 14, No. 8, June 1, 1996, pp. 735-46.
			Laroche et al. "The Immunogenicity and Safety of a New Combined Diphtheria, Tetanus and Poliomyelitis Booster Vaccine (Td-elPV)." <i>Infection</i> . Vol. 27, No. 1, January 1999, pp. 49-56.
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.